1.
Acta Med Port
; 14(4): 375-80, 2001.
Artigo
em Português
| MEDLINE
| ID: mdl-11762177
RESUMO
The efficacy and safety of docetaxel were evaluated in an open, multicentric, non comparative study involving 24 patients with locally advanced or metastatic breast cancer, eligible for second line or subsequent anticancer chemotherapy; the results confirm a global response around 50%, suggesting some advantages when compared to the usual treatments in this set of patients; the median duration of response, the median time to progression and the median time of survival were respectively, 309, 219 and 345 days; the main iatrogenic event was haematological, mainly in the white and red blood cells.
Assuntos
Antineoplásicos Fitogênicos/uso terapêutico , Neoplasias da Mama/tratamento farmacológico , Paclitaxel/análogos & derivados , Paclitaxel/uso terapêutico , Taxoides , Adulto , Idoso , Neoplasias da Mama/patologia , Docetaxel , Feminino , Humanos , Pessoa de Meia-Idade , Metástase Neoplásica , Estadiamento de Neoplasias
2.
Br J Haematol
; 110(1): 238-9, 2000 Jul.
Artigo
em Inglês
| MEDLINE
| ID: mdl-10931009